8229 related articles for article (PubMed ID: 23431672)
1. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
2. [Vemurafenib (Zelboraf) in the therapy of melanoma].
Liszkay G
Magy Onkol; 2013 Jun; 57(2):110-3. PubMed ID: 23795356
[TBL] [Abstract][Full Text] [Related]
3. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous side effects of vemurafenib: a case report and discussion.
Shea SM; Boyd K; Patterson J
Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
[TBL] [Abstract][Full Text] [Related]
6. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
13. Analysis of dermatologic events in vemurafenib-treated patients with melanoma.
Lacouture ME; Duvic M; Hauschild A; Prieto VG; Robert C; Schadendorf D; Kim CC; McCormack CJ; Myskowski PL; Spleiss O; Trunzer K; Su F; Nelson B; Nolop KB; Grippo JF; Lee RJ; Klimek MJ; Troy JL; Joe AK
Oncologist; 2013; 18(3):314-22. PubMed ID: 23457002
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.
Garrido MC; Riveiro-Falkenbach E; Ruano Y; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Jun; 37(6):440-3. PubMed ID: 25357018
[TBL] [Abstract][Full Text] [Related]
16. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
18. Eruptive squamous cell carcinomas after vemurafenib therapy.
Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
[TBL] [Abstract][Full Text] [Related]
19. Drug safety evaluation of vemurafenib in the treatment of melanoma.
Tsai KY; Nowroozi S; Kim KB
Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
